Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Sep;7(5):393-400.
doi: 10.1007/s11908-005-0014-0.

Progress and Emerging Challenges in Preventing Mother-to-Child Transmission

Affiliations

Progress and Emerging Challenges in Preventing Mother-to-Child Transmission

Matthew F Chersich et al. Curr Infect Dis Rep. 2005 Sep.

Abstract

There is a widening gulf between the effectiveness of interventions for preventing mother-to-child transmission (PMTCT) of HIV in sub-Saharan Africa and other regions of the world. Compared with long-course, triple antiretroviral regimens used in Brazil, Europe, and the United States, most countries in sub-Saharan Africa use a less effective regimen consisting of single-dose nevirapine (NVP). Furthermore, the documentation of unacceptable levels of resistance following this regimen makes it prudent to review current PMTCT strategies. Not only is it necessary to review the use of single-dose NVP for PMTCT, but efforts to minimize breast milk transmission of HIV should be enhanced. This review summarizes the programmatic and evidence-based reasons for adopting a standardized approach to long-course, triple-drug MTCT prophylaxis in sub-Saharan Africa. Antiretroviral treatment programs in resource-constrained settings have achieved similar levels of effectiveness as high-income countries, despite adopting standardized approaches to antiretroviral treatment. Similarly, in resource-constrained settings with adequate infrastructure and programmatic capacity, use of standardized, long-course, triple-drug regimens for MTCT prevention are likely to achieve levels of effectiveness seen in Brazil, Europe, and the United States.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Br Med Bull. 2003;67:127-35 - PubMed
    1. J Infect Dis. 2004 Jun 15;189(12):2154-66 - PubMed
    1. J Acquir Immune Defic Syndr. 2002 Jun 1;30(2):216-29 - PubMed
    1. AIDS. 2004 Aug 20;18(12):1661-71 - PubMed
    1. HIV Med. 2001 Oct;2(4):314-34 - PubMed

LinkOut - more resources